NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment

NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment
NovoCure Ltd secures Japan approval

NovoCure Ltd secured approval from Japan’s Ministry of Health, Labour and Welfare for reimbursement of its treatment for non-small cell lung cancer under the country’s National Health Insurance coverage.

This milestone enables increased patient access to the therapy in the Japanese market and marks a significant expansion of NovoCure Ltd’s global reach. Further details were shared in the company’s official press release.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.